Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

12.51
-0.6700-5.08%
Post-market: 12.620.1100+0.88%19:51 EDT
Volume:2.39M
Turnover:30.52M
Market Cap:1.06B
PE:-3.28
High:13.55
Open:13.33
Low:12.47
Close:13.18
52wk High:62.75
52wk Low:5.95
Shares:85.11M
Float Shares:55.47M
Volume Ratio:1.80
T/O Rate:4.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:2.49
PE(LYR):-3.54

Loading ...

Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential

TIPRANKS
·
May 11

MoonLake Q1 net loss widens 71.9% to $69.7 million

Reuters
·
May 11

MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)

TIPRANKS
·
May 11

MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

MoonLake Immunotherapeutics Q1 Net Loss Widens

MT Newswires Live
·
May 11

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

TIPRANKS
·
May 11

MoonLake says aligned with FDA on submission plans for sonelokimab

TIPRANKS
·
May 11

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

TIPRANKS
·
May 11

MoonLake says FDA backs sonelokimab HS BLA plan, filing set for September 2026

Reuters
·
May 10

Moonlake Immunotherapeutics Says U.S. FDA Accepts MIRA And VELA-TEEN Trial Data For Sonelkimab BLA Submission

Reuters
·
May 10

MoonLake Immunotherapeutics - FDA Accepts Mira and Vela-Teen Trial Data for Sonelkimab Bla Submission

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics Announces Positive Outcome From Its Final Pre-Bla Meeting With the U.S. FDA and Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics - Bla Submission for Sonelkimab in Hs Planned for End of September 2026

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 10

Moonlake Immunotherapeutics announces annual shareholder meeting

Reuters
·
Apr 22

MoonLake CFO Matthias Bodenstedt disposes 2,426 shares for $47,444

Reuters
·
Apr 17

Major Insider Move at MoonLake Immunotherapeutics Stirs Investor Attention

TIPRANKS
·
Apr 15

MoonLake CEO Jorge Santos da Silva sells USD 2.7 million shares

Reuters
·
Apr 15

MoonLake CFO Matthias Bodenstedt disposes of USD 1.7 million in common shares

Reuters
·
Apr 11